4-(2,4-difluorobenzyloxy)benzaldehyde | 166049-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2,4-difluorobenzyloxy)benzaldehyde
• 英文别名: 4‐[(2,4‐difluorobenzyl)oxy]benzaldehyde；4-[(2,4-difluorophenyl)methoxy]benzaldehyde
• CAS: 166049-77-0
• 化学式: C₁₄H₁₀F₂O₂
• mdl: MFCD17945286
• 分子量: 248.229
• InChiKey: WXUPOQPNVKZVBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2,4-difluorobenzyloxy)benzaldehyde 在 吡啶 、 氧气 、 铜 、 氯化铵 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 48.0h， 生成 C₂₀H₁₅F₂N₃O
  参考文献：
  名称：

  2-芳基-1，2，2，4-三唑并[1，5-a]吡啶衍生物的合成及抗肿瘤活性。

  摘要：

  合成了一系列新颖的2-芳基-1,2,4-三唑并[1,5-a]吡啶衍生物，并评估了它们在体外对人卵巢癌细胞系（HO-8910）和人肝癌的细胞毒活性。细胞系（贝尔7402）。与顺铂相比，大多数化合物对癌细胞系表现出高或中等活性。测试了其中两个在Bel 7402上的凋亡。

  DOI：

  10.2174/157340610791321505
• 作为产物：
  描述：

  2,4-二氟溴苄 、 对羟基苯甲醛 在 sodium iodide 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 以61 %的产率得到4-(2,4-difluorobenzyloxy)benzaldehyde
  参考文献：
  名称：

  新型苄胺类抗真菌药的合成及其抗真菌药效评价

  摘要：

  由卤素取代的3-和4-苄氧基苯甲醛衍生物与6-甲基庚-2-基胺或正辛胺通过还原胺化合成了一系列23种新型苄胺。在微量稀释测定中针对作为测试微生物的非致病性酵母解脂耶氏酵母评估所得胺的抗真菌活性。还对有前景的化合物进行了针对人类致病性念珠菌的测试。本次筛选研究了苄基醚侧链上卤素取代基的影响，以及与正辛基侧链相比，(±)-6-甲基庚-2-基胺的支化侧链的影响。

  DOI：

  10.1002/ardp.202300381

文献信息

• Quinazoline derivatives as selective CYP1B1 inhibitors
  作者：Mohd Usman Mohd Siddique、Glen J.P. McCann、Vinay R. Sonawane、Neill Horley、Linda Gatchie、Prashant Joshi、Sandip B. Bharate、Venkatesan Jayaprakash、Barij N. Sinha、Bhabatosh Chaudhuri

  DOI：10.1016/j.ejmech.2017.02.032

  日期：2017.4

  potent and specific CYP1B1 inhibitors can lead to a novel treatment of cancer. Flavonoids have a compact rigid skeleton which fit precisely within the binding cavity of CYP1B1. Systematic isosteric replacement of flavonoid 'O' atom with 'N' atom led to the prediction that a 'quinazoline' scaffold could be the basis for designing potential CYP1B1 inhibitors. A total of 20 quinazoline analogs were synthesized

  CYP1B1与乳腺癌，卵巢癌，肾癌，皮肤癌和肺癌的发生有关。有人提出，确定有效的和特定的CYP1B1抑制剂可以导致癌症的新治疗。类黄酮具有紧密的刚性骨架，可以精确地装配在CYP1B1的结合腔内。用“ N”原子对类黄酮“ O”原子进行系统等位取代，导致预测“喹唑啉”骨架可能是设计潜在CYP1B1抑制剂的基础。合成了总共20种喹唑啉类似物，并在Sacchrosomes™中筛选了CYP1B1和CYP1A1抑制作用。六种具有抑制CYP1B1能力的化合物的IC50测定结果表明，喹唑啉5c和5h是CYP1B1抑制作用的最佳候选者，IC50值在nM范围内。属于CYP1，CYP2和CYP3酶家族的同源CYP的进一步选择性研究表明，这些化合物可能没有关键的药物相互作用。进行分子建模研究以合理化所观察到的酶促抑制作用。对具有CYP1A1和CYP1B1酶的活酵母和人细胞的进一步生物学研究表明，最有效的化合物具有
• Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders
  作者：Xiaozheng Dou、Dinesh Nath、Henry Shin、Elmar Nurmemmedov、Philip C. Bourne、Jian-Xing Ma、Adam S. Duerfeldt

  DOI：10.1021/acs.jmedchem.9b01189

  日期：2020.3.26

  Peroxisome proliferator-activated receptor alpha (PPAR alpha) is expressed in retinal Muller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPAR alpha with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPAR alpha is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPAR alpha over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.
• Novel aryloxy azolyl chalcones with potent activity against Mycobacterium tuberculosis H37Rv
  作者：Vijay K. Marrapu、Vinita Chaturvedi、Shubhra Singh、Shyam Singh、Sudhir Sinha、Kalpana Bhandari

  DOI：10.1016/j.ejmech.2011.06.037

  日期：2011.9

  A series of twenty seven novel aryloxy azolyl chalcones were synthesized and evaluated in vitro for the growth inhibition of Mycobacterium tuberculosis H37Rv. Ten compounds from this series exhibited good activity with MIC in the range of 3.12-0.78 mu g/mL and six of them were found non-toxic against VERO cells and MBMDMos (mouse bone-marrow derived macrophages), were further evaluated ex-vivo for their potential to kill intracellular bacilli. Two compounds 4 and 19 showed 99% and 71% killing respectively, of intracellular bacilli in MBMDMos infection model. Further, compound 19, an imidazolyl chalcone with a 2,4-difluorobenzyloxy moiety also exhibited moderate in vivo activity in mice against virulent M. tuberculosis, thus providing a new structural lead towards TB drug development. (C) 2011 Elsevier Masson SAS. All rights reserved.
• Silvestri; Pagnozzi; Troccoli, Il Farmaco, 1995, vol. 50, # 4, p. 227 - 238
  作者：Silvestri、Pagnozzi、Troccoli、Stefancich、Massa、Apuzzo、Perazzi、Artico、Simonetti

  DOI：——

  日期：——
• Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy
  作者：Vinay Sonawane、Mohd Usman Mohd Siddique、Surender Singh Jadav、Barij Nayan Sinha、Venkatesan Jayaprakash、Bhabatosh Chaudhuri

  DOI：10.1016/j.ejmech.2019.01.011

  日期：2019.3

  Inhibition of cyclin dependent kinase 4 (Cdk4) prevents cancer cells from entering the early G(0)/G(1) phase of the cell division cycle whereas inhibiting tubulin polymerization blocks cancer cells' ability to undergo mitosis (M) late in the cell cycle. We had reported earlier that two non-planar and relatively non-toxic fascaplysin derivatives, an indole and a tryptoline, inhibit Cdk4 with IC50 values of 6.2 and 10 mu M, respectively. Serendipitously, we had also found that they inhibited tubulin polymerization. The molecules were efficacious in mouse tumor models. We have now identified Cink4T in a 59-compound quinazolinone library, designed on the basis of ligand-based virtual screening, as a compound that inhibits Cdk4 and tubulin. Its IC50 value for Cdk4 inhibition is 0.47 mu M and >50 mu M for inhibition of Cdk1, Cdk2, Cdk6, Cdk9. Cink4T inhibits tubulin polymerization with an IC50 of 0.6 mu M. Molecular modelling studies on Cink4T with Cdk4 and tubulin crystal structures lend support to these observations. Cancer cell cycle analyses confirm that Cink4T blocks cells at both G(0)/G(1) and M phases as it should if it were to inhibit both Cdk4 and tubulin polymerization. Our results show, for the very first time, that virtual screening can be used to design novel inhibitors that can potently block two crucial phases of the cell division cycle. (C) 2019 Elsevier Masson SAS. All rights reserved.